The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates

Human Pathology

Volumn 29, Issue 2, 1998, Pages 146-154

  Nakopoulou, Lydia ^a   Vourlakou, Christina ^a   Zervas, Anastasios ^a   Tzonou, Anastasia ^a   Gakiopoulou, Hariklia ^a   Dimopoulos, Meletios Athanasios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bcl 2; Ki 67; P53; Transitional cell carcinoma

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CLINICAL EXAMINATION; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TRANSITIONAL CELL CARCINOMA;

EID: 0031884935     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90225-8     Document Type: Article

References (41)

1. Cohen SM, Ellwein LB: Genetic errors, cell proliferation and carcinogenesis. Cancer Res 51:6493-6505, 1991
2. Kerr JF, Winterford CM, Harmon BV: Apoptosis: Its significance in cancer and cancer therapy. Cancer 73:2013-2026, 1994
3. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6, 1994
4. Williams GT: Programmed cell death: Apoptosis and oncogenesis. Cell 65:1097-1098, 1991
5. Tsujimoto Y, Cossman J, Jaffe E, et al: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443, 1985
6. Carson DA, Ribeiro JM: Apoptosis and disease. Lancet 341: 1251-1254, 1993
7. Hockenbery DM, Zutter M, Hickey W, et al: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A 88:6961-6965, 1991
8. Doglioni C, Dei Tos AP, Laurino L, et al: The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates with particular reference to oestrogen receptor status. Virchows Arch 424:47-51, 1994
9. Pezzella F, Turley H, Kuzu I, et al: Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690-694, 1993
10. Baretton GB, Diebold J, Christoforis G, et al: Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer 77:255-264, 1996
11. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p53 tumor supressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
12. Miyashita T, Krajewski S, Krajewska M, et al: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805, 1994
13. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
14. Lipponen PK: Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 53:365-370, 1993
15. Kruger S, Muller H: Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas. Br J Urol 75:480-484, 1995
16. Furihata M, Sonobe H, Ohtsuki Y, et al: Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia. J Pathol 178:133-139, 1996
17. Lipponen PK, Aaltomaa S, Eskelinen M: Expression of the apoptosis suppressing bcl-2 protein in transitional ceil bladder tumours. Histopathology 28:135-140, 1996
18. Pilotti S, Collini P, Rilke F, et al: Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 172:337-342, 1994
19. Verhaegh MEJM, Sanders CJG, Arends JW, et al: Expression of the apoptosis-suppressing protein bcl-2 in non-melanoma skin cancer. Br J Dermatol 132:740-744, 1995
20. Vaux DL, Cory S, AdamsJM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442, 1988
21. McDonnell TJ, Deane N, Platt FM, et al: Bcl-2 immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphe-proliferation. Cell 57:79-88, 1989
22. King ED, Matteson J, Jacobs SC, et al: Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: Association with tumor progression. J Urol 155:316-320, 1996
23. Stewart BW: Mechanism of apoptosis: Integration of genetic, biochemical and cellular indicators. J Natl Cancer Inst 86:1286-1298, 1994
24. Diebold J, Baretton G, Felchner M, et al: Bcl-2 expression, p53 accumulation and apoptosis in ovarian carcinomas. Am J Clin Pathol 105:341-349, 1996
25. Yin XM, Oltval ZN, Korsmeyer SJ: BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerisation with Bax. Nature 369:321-323, 1994
26. Nakopoulou L, Constantinides C, Papandropoulos J, et al: Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: Comparison with DNA ploidy. Urology 46:334-339, 1995
27. Spruck CHI, Ohneseit PF, Gonzalez ZM, et al: Two molecular pathways to transitional-cell carcinoma of the bladder. Cancer Res 54:784-788, 1994
28. Lipponen PK: Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int J Cancer 53:365-370, 1993
29. Lipponen PK, Eskelinen MJ, Nordling S: Progression and survival in transitional-cell bladder cancer: A comparison of established prognostic factors, S-phase fraction and DNA-ploidy. Eur J Cancer 27:877-881, 1991
30. Martin HM, Filipe MI, Morris RW, et al: p53 expression and prognosis in gastric carcinoma. IntJ Cancer 50:859-862,1992
31. Miyamoto H, Kubota Y, Shuin T, Analyses of p53 gene mutations in primary human bladder cancer. Oncol Res Int J 5:245-249, 1993
32. Zhang ZF, Sarkis AS, Cordon-Cardo C, et al: Tobacco smoking occupation and p53 nuclear overexpression in early stage bladder cancer. Cancer Epidemiol Biomarkers Prev 3:19-24, 1994
33. Tenti P, Zappatore R, Romagnoli S, et al: p53 overexpression and human papillomavirus infection in transitional cell carcinoma of the urinary bladder. Correlation with histological parameters. J Pathol 178:65-70, 1996
34. Lane D: p53, guardian of the genome. Nature (Lond) 358:15-16, 1992
35. Halder S, Negrini M, Monne M, et al: Down regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54:2095-2097, 1994
36. Hockenbery DM, Zutter M, Hickey W, et al: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A 88:6961-6965, 1991
37. Yonish-Rouach E, Rensmitzki D, Lotem J, et al: Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature 352:345-347, 1991
38. Coates PJ, Hales SA, Hall PA: The association between cell proliferation and apoptosis: Studies using the cell cycle-associated proteins Ki-67 and DNA polymerase alpha. J Pathol 178:71-77, 1996
39. Cattoretti G, Rilke F, Andreola S, et al: p53 expression in breast cancer. Int J Cancer 41:178-183, 1988
40. Saegusa M, Takano Y, Okayasu I: Bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasia. J Cancer Res Clin Oncol 121:357-363, 1995
41. Gorczyca W, Markiewski M, Kram A, et al: Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: Their correlation widi Ki-67 growth fraction. Virchows Arch 426:229-233, 1995